术前放化疗中反应为中等的 II/III 期直肠癌:我们是否有个体化风险分层的指征?
Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification?
机构信息
Department of General and Visceral Surgery, University Medical Center Göttingen, Georg-August-University, Göttingen, Germany.
出版信息
World J Surg Oncol. 2010 Apr 13;8:27. doi: 10.1186/1477-7819-8-27.
BACKGROUND
Response to preoperative radiochemotherapy (RCT) in patients with locally advanced rectal cancer is very heterogeneous. Pathologic complete response (pCR) is accompanied by a favorable outcome. However, most patients show incomplete response. The aim of this investigation was to find indications for risk stratification in the group of intermediate responders to RCT.
METHODS
From a prospective database of 496 patients with rectal adenocarcinoma, 107 patients with stage II/III cancers and intermediate response to preoperative 5-FU based RCT (ypT2/3 and TRG 2/3), treated within the German Rectal Cancer Trials were studied. Surgical treatment comprised curative (R0) total mesorectal excision (TME) in all cases. In 95 patients available for statistical analyses, residual transmural infiltration of the mesorectal compartment, nodal involvement and histolologic tumor grading were investigated for their prognostic impact on disease-free (DFS) and overall survival (OS).
RESULTS
Residual tumor transgression into the mesorectal compartment (ypT3) did not influence DFS and OS rates (p = 0.619, p = 0.602, respectively). Nodal involvement after preoperative RCT (ypN1/2) turned out to be a valid prognostic factor with decreased DFS and OS (p = 0.0463, p = 0.0236, respectively). Persistent tumor infiltration of the mesorectum (ypT3) and histologic tumor grading of residual tumor cell clusters were strongly correlated with lymph node metastases after neoadjuvant treatment (p < 0.001).
CONCLUSIONS
Advanced transmural tumor invasion after RCT does not affect prognosis when curative (R0) resection is achievable. Residual nodal status is the most important predictor of individual outcome in intermediate responders to preoperative RCT. Furthermore, ypT stage and tumor grading turn out to be additional auxiliary factors. Future clinical trials for risk-adapted adjuvant therapy should be based on a synopsis of clinicopathologic parameters.
背景
局部晚期直肠癌患者对术前放化疗(RCT)的反应差异很大。病理完全缓解(pCR)与良好的预后相关。然而,大多数患者的反应并不完全。本研究旨在寻找 RCT 中中度反应患者的风险分层指标。
方法
从 496 例直肠腺癌患者的前瞻性数据库中,选择 107 例接受术前基于 5-FU 的 RCT(ypT2/3 和 TRG 2/3)的 II/III 期癌症和中度反应患者进行研究。所有患者均接受根治性(R0)全直肠系膜切除术(TME)治疗。在 95 例可进行统计分析的患者中,研究了直肠系膜中残留的穿透性肿瘤浸润、淋巴结受累和组织学肿瘤分级对无病生存(DFS)和总生存(OS)的预后影响。
结果
肿瘤向直肠系膜的残留穿透(ypT3)不影响 DFS 和 OS 率(p = 0.619,p = 0.602)。术前 RCT 后的淋巴结受累(ypN1/2)是一个有效的预后因素,DFS 和 OS 降低(p = 0.0463,p = 0.0236)。新辅助治疗后残留肿瘤细胞簇的直肠系膜中持续肿瘤浸润和组织学肿瘤分级与淋巴结转移密切相关(p < 0.001)。
结论
当可实现根治性(R0)切除时,RCT 后穿透性肿瘤侵犯程度不会影响预后。残留淋巴结状态是术前 RCT 中中度反应患者个体预后的最重要预测因素。此外,ypT 分期和肿瘤分级也是辅助因素。未来的风险适应性辅助治疗临床试验应基于临床病理参数的综合分析。